Immunomodulatory potential of dexmedetomidine in perioperative pain management for patients with cancer
Year: 2025
Type: article
Abstract: •Dexmedetomidine (DEX) has immunomodulatory effects in perioperative pain management.•DEX can reduce pro-inflammatory cytokines.•DEX has dose-dependent effects on tumor progression.•Optimizing DEX dosing may improve the therapeutic outcomes of cancer surgery.•Further research is needed to clarify DEX's impact on cancer recurrence and survival, as the findings remain mixed.
Source: Cancer Pathogenesis and Therapy
Authors: Yuxian Liu, He Ma, Xintong Wang, Isabelle Yang, Jingping Wang
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $1,100
Funder: Massachusetts General Hospital
OpenAlex ID: W4406072002
